The PHS 340B Drug Pricing Program: Results of a Survey of Eligible Entities

The PHS 340B Drug Pricing Program: Results of a Survey of Eligible Entities

Published: Aug 30, 2004
Publisher: Cambridge, MA: Mathematica Policy Research
Download
Authors

Robert Schmitz

So Limpa-Amara

Julita Milliner-Waddell

Frank Potter

Escalating drug prices have affected safety net providers in serious ways. This report studies providers eligible to purchase prescription drugs at a discount under the 340B program, which requires manufacturers that receive reimbursement from Medicaid to provide reduced prices to more than 10,000 qualified health care clinics, centers, and hospitals in the U.S. These providers in turn serve more than 10 million people in all 50 states. The findings suggest that the program has led to significant savings and a high level of satisfaction for providers enrolled in it. In its absence, providers would probably serve fewer patients, charge higher prices for prescription drugs, and incur greater losses.

How do you apply evidence?

Take our quick four-question survey to help us curate evidence and insights that serve you.

Take our survey